AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results…
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results…
At the American Academy of Neurology (AAN) 2026 annual conference, Cerevance reported findings from the Phase II ASCEND (NCT06006247) trial…
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, BlueRock Therapeutics, a wholly owned, independently operated subsidiary…
On April 20, at the 2026 American Academy of Neurology (AAN) meeting, Cabaletta Bio announced positive results from the Phase…
On 20 April, at the 2026 American Academy of Neurology (AAN) meeting, Argenx announced positive results from the Phase III,…
On 20 April, at the American Academy of Neurology (AAN) 2026 Annual Meeting, Sanofi presented three-year data from the open-label…
On 19 April, at the 2026 American Academy of Neurology (AAN) meeting, in the late-breaking science session, Xenon Pharmaceuticals announced…
An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator (DTA) has…
Alar Pharmaceuticals’ long-acting, ketamine-based therapy has shown early signs of symptom improvement in treatment-resistant depression (TRD) in a Phase I…
Amyotrophic lateral sclerosis (ALS) is a progressive disorder that affects motor neurons responsible for controlling voluntary muscle movement. As these…